| Heading: |
Prescriptions |
| Question ID: |
1813722 |
| UIN: |
60649 |
| House: |
Commons |
| Date tabled: |
2025-06-17 |
| Asking Member ID: |
4781 |
| Asking Member display name: |
Dr Luke Evans
|
| Asking Member handle: |
drlukeevans
|
| Asking Member Twitter reference: |
@drlukeevans
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the Medicines and Healthcare products Regulatory Agency on reducing overprescribing. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-03 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
I have discussed with the Medicines and Healthcare products Regulatory Agency (MHRA) concerns raised by Members of Parliament about the adverse effects of antidepressant prescribing, and what the MHRA can do to improve communication on the risks of differ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |